Trametinib DMSO solvateAllosteric MEK1/MEK2 kinase inhibitor CAS# 1187431-43-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1187431-43-1 | SDF | Download SDF |
PubChem ID | 50992434 | Appearance | Powder |
Formula | C28H29FIN5O5S | M.Wt | 693.53 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | GSK-1120212 DMSO solvate; Trametinib; JTP-74057; GSK1120212 | ||
Solubility | DMSO : 69 mg/mL (99.49 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide;methylsulfinylmethane | ||
SMILES | CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC(=CC=C4)NC(=O)C)C5CC5.CS(=O)C | ||
Standard InChIKey | OQUFJVRYDFIQBW-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C26H23FIN5O4.C2H6OS/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34;1-4(2)3/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34);1-2H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Trametinib DMSO solvate is a potent MEK inhibitor that specifically inhibits MEK1/2, with an IC50 value of about 2 nM.In Vitro:In BRAF mutant SK-MEL-28 cells and KRAS mutant HCT116 cells, Trametinib (GSK1120212) DMSO solvate causes dose-dependent inhibition of ERK1/2 phosphorylation as well as dose-dependent growth inhibition. In both SK-MEL-28 and HCT116 cells, Trametinib DMSO solvate inhibits 50% p-ERK1/2 at nearly equivalent concentrations (0.8 and 1.8 nM, respectively). However, as the slopes of the curves reflect, in SK-MEL-28 cells, Trametinib DMSO solvate inhibits 90% p-ERK1/2 at a lower concentration (3.4 nM) than in HCT116 (33.3 nM). Furthermore, in both cell lines, 50% growth inhibition is only achieved at concentrations Trametinib DMSO solvate that produces near complete ERK1/2 inhibition (85 and 90%, respectively)[2].In Vivo:Trametinib (GSK1120212) DMSO solvate is evaluated in vivo in an A549 (KRAS mutant cell line) xenograft model, orally dosing daily for 21 days (qd×21). In this study, near complete tumor growth inhibition is observed at 5.0 and 2.5 mg/kg [92 and 87% tumor growth inhibition (TGI), respectively] and to a lesser degree at 0.5 and 0.1 mg/kg (62 and 58% TGI). Although 5 mg/kg is the maximally tolerated dose (MTD) in this study, 3 mg/kg is the typically observed MTD. Dose-dependent antitumor activity with Trametinib DMSO solvate treatment has been similarly reported for several other KRAS and BRAF mutant tumor models[2]. References: |
Trametinib DMSO solvate Dilution Calculator
Trametinib DMSO solvate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.4419 mL | 7.2095 mL | 14.419 mL | 28.838 mL | 36.0475 mL |
5 mM | 0.2884 mL | 1.4419 mL | 2.8838 mL | 5.7676 mL | 7.2095 mL |
10 mM | 0.1442 mL | 0.7209 mL | 1.4419 mL | 2.8838 mL | 3.6047 mL |
50 mM | 0.0288 mL | 0.1442 mL | 0.2884 mL | 0.5768 mL | 0.7209 mL |
100 mM | 0.0144 mL | 0.0721 mL | 0.1442 mL | 0.2884 mL | 0.3605 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Trametinib (also known as GSK1120212 or JTP 74057), originally identified as a p15 inductive compound, is a novel and potent allosteric inhibitor of MEK kinase, which exhibits ATP non-competitive inhibition against MEK1 and MEK2 kinase. It has demonstrated broad antitumor activities in a variety of tumor xgenograft models, including HT-29 and COLO205 colorectal tumor cell lines. Trametinib induces expression of p15 and p27, reduces cyclin D1 levels, and causes dephosphorylation of RB protein and G1-phase arrest with a reduction of TS expression in HT-29 cells. It also effectively inhibits p-ERK 1/2 resulting in cell growth inhibition in tumor cell lines harboring B-RAF mutant.
Reference
1.Akintunde Akinleye, Muhammad Furqan, Nikhil Mukhi, Pavan Ravella and Delong Liu. MEK and the inhibitors: from bench to bedside. Journal of Hematology & Oncology 2013, 6:27
2.Motoki Watanabe, Yoshihiro Sowa, Mayumi Yogosawa and Toshiyuki Sakai. Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells. Cancer Sci 2013; 104(6): 687-693
- Cuniloside B
Catalog No.:BCN6062
CAS No.:1187303-40-7
- Resminostat hydrochloride
Catalog No.:BCC1888
CAS No.:1187075-34-8
- H-Cys(Me)-OH
Catalog No.:BCC2908
CAS No.:1187-84-4
- 11-Hydroxycodaphniphylline
Catalog No.:BCN6061
CAS No.:1186496-68-3
- Evacetrapib (LY2484595)
Catalog No.:BCC2329
CAS No.:1186486-62-3
- TMN 355
Catalog No.:BCC6121
CAS No.:1186372-20-2
- Epivogeloside
Catalog No.:BCN6060
CAS No.:118627-52-4
- 4SC-202
Catalog No.:BCC5359
CAS No.:1186222-89-8
- ALW-II-41-27
Catalog No.:BCC1350
CAS No.:1186206-79-0
- NPE-caged-proton
Catalog No.:BCC7698
CAS No.:1186195-63-0
- MTEP hydrochloride
Catalog No.:BCC1780
CAS No.:1186195-60-7
- Tocrifluor T1117
Catalog No.:BCC7401
CAS No.:1186195-59-4
- PF 184
Catalog No.:BCC6130
CAS No.:1187460-81-6
- Baricitinib (LY3009104, INCB028050)
Catalog No.:BCC2195
CAS No.:1187594-09-7
- Baricitinib phosphate
Catalog No.:BCC1401
CAS No.:1187595-84-1
- Carabrolactone A
Catalog No.:BCN6063
CAS No.:1187925-30-9
- Carabrolactone B
Catalog No.:BCN6064
CAS No.:1187925-31-0
- Diosbulbin I
Catalog No.:BCN6065
CAS No.:1187951-05-8
- Diosbulbin J
Catalog No.:BCN6066
CAS No.:1187951-06-9
- Ac-Leu-OH
Catalog No.:BCC2967
CAS No.:1188-21-2
- ent-14,16-Epoxy-8-pimarene-3,15-diol
Catalog No.:BCN6067
CAS No.:1188281-98-2
- 7-Hydroxydarutigenol
Catalog No.:BCN6068
CAS No.:1188281-99-3
- 9-Hydroxydarutigenol
Catalog No.:BCN6069
CAS No.:1188282-00-9
- 16-O-Acetyldarutigenol
Catalog No.:BCN6070
CAS No.:1188282-01-0